Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: An in vivo microdialysis study

Neuroendocrinology

Volumn 76, Issue 3, 2002, Pages 148-157

  Pacak, Karel ^a   Tjurmina, Olga ^d   Palkovits, Miklós ^b   Goldstein, David S ^a   Koch, Christian A ^d   Hoff, Thomas ^c   Chrousos, George P ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c HUMBOLDT UNIVERSITY   (Germany)

^d Building 10 ^*

Author keywords

Adrenal steroids; Amino acid decarboxylase; Catecholamines; Dihydroxyphenylacetic acid; Dihydroxyphenylalanine; Homovanillic acid; Nucleus accumbens; Prefrontal cortex

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; AMINO ACID DECARBOXYLASE; DIHYDROXYPHENYLACETIC ACID; DOPA; DOPAMINE; HOMOVANILLIC ACID; HYDROCORTISONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; HYPERCORTISOLISM; INFUSION; INTERSTITIAL FLUID; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; OSMOTIC MINIPUMP; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CHRONIC DISEASE; DOPA DECARBOXYLASE; DOPAMINE; ENZYME INHIBITORS; HOMOVANILLIC ACID; HYDRAZINES; HYPERCHOLESTEROLEMIA; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036976830     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064522     Document Type: Article

References (77)

1. Starkman MN, Schteingart DE, Schork MA: Depressed mood and other psychiatric manifestations of Cushing's syndrome: Relationship to hormone levels. Psychosom Med 1981;43:3-18.
2. Dorn LD, Burgess ES, Dubbert B, Simpson SE, Friedman T, Kling M, Gold PW, Chrousos GP: Psychopathology in patients with endogenous Cushing's syndrome: 'Atypical' or melancholic depression. Clin Endocrinol (Oxford) 1995;43:433-442.
3. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP: The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997;82:912-919.
4. Starkman MN, Schteingart DE, Schork MA: Cushing's syndrome after treatment: Changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res 1986;19:177-188.
5. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrinol Rev 1996;17:187-205.
6. Deuschle M, Schweiger U, Weber B, Gotthardt U, Korner A, Schmider J, Standhardt H, Lammers CH, Heuser I: Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997;82:234-238.
7. Gold PW, Chrousos GP: The endocrinology of melancholic and atypical depression: Relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999;111:22-34.
8. Lindley SE, Bengoechea TC, Schatzberg AF, Wong DL: Glucocorticoid effects on mesotelencephalic dopamine neurotransmission. Neuropsychopharmacology 1999;21:399-407.
9. Piazza PV, Rouge-Pont F, Deroche V, Maccari S, Simon S, Le Moal M: Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci USA 1996;93:8716-8720.
10. Rothschild AJ, Langlais PJ, Schatzberg AF, Miller MM, Saloman MS, Lerbinger JE, Cole JO, Bird ED: The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. Life Sci 1985;36:2491-2501.
11. Fuxe K, Hökfelt T, Johansson O, Jonsson G, Lidbrink P, Ljungdahl A: The origin of the dopamine nerve terminals in limbic and frontal cortex. Evidence for meso-cortico dopamine neurons. Brain Res 1974;82:349-355.
12. Lindvall O, Björklund A: The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method. Acta Physiol Scand Suppl 1974;412:1-48.
13. Björklund A, Lindvall O: Dopamine-containing systems in the CNS; in Bjorklund A, Hokfelt T (eds): Handbook of Chemical Neuroanatomy. 1. Classical Transmitters in the CNS. New York, Elsevier, 1984, vol 2, pp 55-122.
14. Fallon JH, Moore RY: Catecholamine innervation of the basal forebrain. 4. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol 1978;180:545-580.
15. Willner P: Animal models as simulations of depression. Trends Pharmacol Sci 1991;12:131-136.
16. Drevets WC, Price JL, Jr, Todd RD, Reich T, Vannier M, Raichle ME: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-827.
17. Kapur S, Mann JJ: Role of the dopaminergic system in depression. Biol Psychiatry 1992;32: 1-17.
18. Wise RA, Rompre PP: Brain dopamine and reward. Annu Rev Psychol 1989;40:191-225.
19. Wise RA: Addiction becomes a brain disease. Neuron 2000;26:27-33.
20. Le Moal M, Simon H: Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol Rev 1991;71:155-234.
21. Cabib S, Puglisi-Allegra S: Genotype-dependent effects of chronic stress on apomorphine-induced alterations of striatal and mesolimbic dopamine metabolism. Brain Res 1991;542:91-96.
22. Berridge KC, Robinson TE: What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res Rev 1998;28:309-369.
23. Cummings JL: Frontal-subcortical circuits and human behavior. J Psychosom Res 1998;44:627-628.
24. Ikemoto S, Panksepp J: The role of nucleus accumbens dopamine in motivated behavior: A unifying interpretation with special reference to reward-seeking. Brain Res Rev 1999;31:6-41.
25. Willner P: The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997;12(suppl 3):S7-S14.
26. Theohar C, Fischer-Cornelssen K, Akesson HO, Ansari J, Gerlach J, Harper P, Ohman R, Ose E, Stegink AJ: Bromocriptine as antidepressant: Double blind comparative study with imipramine in psychogenic and endogenous depression. Curr Ther Res 1981;30:830-841.
27. Mansbach RS, Rovetti CC, Freedland CS: The role of monoamine neurotransmitter systems in the nicotine discriminative stimulus. Drug Alcohol Depend 1998;52:125-134.
28. Koob GF, Le Moal M: Drug abuse: Hedonic homeostatic dysregulation. Science 1997;278:52-58.
29. Pani L, Porcella A, Gessa GL: The role of stress in the pathophysiology of the dopaminergic system. Mol Psychiatry 2000;5:14-21.
30. Drevets WC, Ongur D, Price JL: Neuroimaging abnormalities in the subgenual prefrontal cortex: Implications for the pathophysiology of familial mood disorders. Mol Psychiatry 1998;3:190-191, 220-226.
31. Cabib S, Puglisi-Allegra S: Stress, depression and the mesolimbic dopamine system. Psychopharmacology (Berl) 1996;128:331-342.
32. Brown AS, Gershon S: Dopamine and depression. J Neural Transm 1993;91:75-109.
33. Di Chiara G, Loddo P, Tanda G: Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: Implications for the psychobiology of depression. Biol Psychiatry 1999;46:1624-1633.
34. Finlay JM, Damsma G, Fibiger HC: Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration. Psychopharmacology (Berl) 1992;106:202-208.
35. Anisman H, Remington G, Sklar LS: Effect of inescapable shock on subsequent escape performance: Catecholamine and cholinergic mediation of response initiation and maintenance. Psychopharmacology (Berl) 1979;61:107-124.
36. Zangen A, Overstreet DH, Yadid G: Increased catecholamine levels in specific brain regions of a rat model of depression: Normalization by chronic antidepressant treatment. Brain Res 1999;824:243-250.
37. Di Chiara G, Tanda G: Blunting of reactivity of dopamine transmission to palatable food: A biochemical marker of anhedonia in the CMS model? Psychopharmacology (Berl) 1997;134:351-353; discussion 371-377.
38. Rouge-Pont F, Deroche V, Le Moal M, Piazza PV: Individual differences in stress-induced dopamine release in the nucleus accumbens are influenced by corticosterone. Eur J Neurosci 1998;10:3903-3907.
39. Piazza PV, Barrot M, Rouge-Pont F, Marinelli M, Maccari S, Abrous DN, Simon H, Le Moal M: Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Proc Natl Acad Sci USA 1996;93:15445-15450.
40. Barrot M, Marinelli M, Abrous DN, Rouge-Pont F, Le Moal M, Piazza PV: The dopaminergic hyper-responsiveness of the shell of the nucleus accumbens is hormone-dependent. Eur J Neurosci 2000;12:973-979.
41. Gjerris A, Werdelin L, Rafaelsen OJ, Alling C, Christensen NJ: CSF dopamine increased in depression: CSF dopamine, noradrenaline and their metabolites in depressed patients and in controls. J Affect Disord 1987;13:279-286.
42. Pacak K, Yadid G, Jakab G, Lenders JW, Kopin IJ, Goldstein DS: In vivo hypothalamic release and synthesis of catecholamines in spontaneously hypertensive rats. Hypertension 1993;22:467-478.
43. Pacak K, Palkovits M, Kvetnansky R, Matern P, Hart C, Kopin IJ, Goldstein DS: Catecholaminergic inhibition by hypercortisolemia in the paraventricular nucleus of conscious rats. Endocrinology 1995;136:4814-4819.
44. Szemeredi K, Bagdy G, Stull R, Calogero AE, Kopin IJ, Goldstein DS: Sympathoadrenomedullary inhibition by chronic glucocorticoid treatment in conscious rats. Endocrinology 1988;123:2585-2590.
45. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 2. San Diego, Academic Press, 1986.
46. Tjurmina OA, Goldstein DS, Palkovits M, Kopin IJ: α2-Adrenoceptor-mediated restraint of norepinephrine synthesis, release, and turnover during immobilization in rats. Brain Res 1999;826:243-252.
47. Holmes C, Eisenhofer G, Goldstein DS: Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994;653:131-138.
48. Zetterström T, Sharp T, Collin AK, Ungerstedt U: In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur J Pharmacol 1988;148:327-334.
49. Hunter LW, Rorie DK, Tyce GM: Inhibition of aromatic L-amino acid decarboxylase under physiological conditions: Optimization of 3-hydroxybenzylhydrazine concentration to prevent concurrent inhibition of monoamine oxidase. Biochem Pharmacol 1993;45:1363-1366.
50. Angulo JA, McEwen BS: Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens. Brain Res Rev 1994;19:1-28.
51. Horger BA, Roth RH: The role of mesoprefrontal dopamine neurons in stress. Crit Rev Neurobiol 1996;10:395-418.
52. Piazza PV, Le Moal M: Glucocorticoids as a biological substrate of reward: Physiological and pathophysiological implications. Brain Res Rev 1997;25:359-372.
53. Roy A, Karoum F, Pollack S: Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry 1992;49:447-450.
54. Sullivan RM, Gratton A: Relationships between stress-induced increses in medial pre-frontal cortical dopamine and plasma corticosterone levels in rats: Role of cerebral laterality. Neuroscience 1997;83:81-91.
55. Fibiger HC: Neurobiology of depression: Focus on dopamine. Adv Biochem Psychopharmacol 1995;49:1-17.
56. Abercrombie ED, Keefe KA, DiFrischia DS, Zigmond MJ: Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem 1989;52:1655-1658.
57. Thomas DN, Post RM, Pert A: Central and systemic corticosterone differentially affect dopamine and norepinephrine in the frontal cortex of the awake freely moving rat. Ann NY Acad Sci 1994;746:467-469.
58. Dunn AJ: Stress-related changes in cerebral catecholamine and indoleamine metabolism: Lack of effect of adrenalectomy and corticosterone. J Neurochem 1988;51:406-412.
59. Inoue T, Koyama T: Effects of acute and chronic administration of high-dose corticosterone and dexamethasone on regional brain dopamine and serotonin metabolism in rats. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:147-156.
60. Deutch YA, Clark WA, Roth RH: Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 1990;521:311-315.
61. Espejo EF, Minano FJ: Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test. Neuroscience 1999;88:609-615.
62. Doherty MD, Gratton A: Medial prefrontal cortical D1 receptor modulation of the meso-accumbens dopamine response to stress: An electrochemical study in freely-behaving rats. Brain Res 1996;715:86-97.
63. Brake WG, Flores G, Francis D, Meaney MJ, Srivastava LK, Gratton A: Enhanced nucleus accumbens dopamine and plasma corticosterone stress responses in adult rats with neonatal excitotoxic lesions to the medial prefrontal cortex. Neuroscience 2000;96:687-695.
64. Vezina P, Blanc G, Glowinski J, Tassin JP: Opposed behavioral outputs of increased dopamine transmission in prefrontocortical and subcortical areas: A role for cortical D1 receptor. Eur J Neurosci 1991;3:1001-1007.
65. Weihmüller FB, O'Dell SJ, Cole BN, Marshall JF: MK-801 attenuates the dopamine-releasing but not the behavioral effects of methamphetamine: An in vivo microdialysis study. Brain Res 1991;549:230-235.
66. Swerdlow NR, Koob GF: Dopamine, schizophrenia, mania, and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav Brain Sci 1987;10:197-245.
67. Yadid G, Pacak K, Kopin IJ, Goldstein DS: Modified microdialysis probe for sampling extracellular fluid and administering drugs in vivo. Am J Physiol 1993;265:R1205-R1211.
68. Pacak K, Palkovits M, Kopin IJ, Goldstein DS: Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-adrenocortical and sympathoadrenal activity: In vivo microdialysis studies. Front Neuroendocrinol 1995;16:89-150.
69. Lindvall O, Björklund A, Divac I: Organization of mesencephalic dopamine neurons projecting to neocortex and septum. Adv Biochem Psychopharmacol 1977;16:39-46.
70. Loughlin SE, Fallon JH: Substantia nigra and ventral tegmental area projections to cortex: Topography and collateralization. Neuroscience 1984;11:425-435.
71. Louilot A, Le Moal M, Simon H: Opposite influences of dopaminergic pathways to the prefrontal cortex or the septum on the dopaminergic transmission in the nucleus accumbens. An in vivo voltammetric study. Neuroscience 1989;29:45-56.
72. Berendse HW, Galis-de Graaf Y, Groenewegen HJ: Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J Comp Neurol 1992;316:314-347.
73. Brog JS, Salyapongse A, Deutch AY, Zahm DS: The patterns of afferent innervation of the core and shell in the 'accumbens' part of the rat ventral striatum: Immunohistochemical detection of retrogradely transported fluoro-gold. J Comp Neurol 1993;338:255-278.
74. Taber MT, Fibiger HC: Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: Modulation by metabotropic glutamate receptors. J Neurosci 1995;15:3896-3904.
75. King D, Finlay JM: Loss of dopamine terminals in the medial prefrontal cortex increased the ratio of DOPAC to DA in tissue of the nucleus accumbens shell: Role of stress. Brain Res 1997;767:192-200.
76. King D, Zigmond MJ, Finlay JM: Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extra-cellular dopamine in the nucleus accumbens core and shell. Neuroscience 1997;77:141-153.
77. Abercrombie ED, DeBoer P, Heeringa MJ: Biochemistry of somatodendritic dopamine release in substantia nigra: An in vivo comparison with striatal dopamine release. Adv Pharmacol 1998;42:133-136.